Compare Teradyne, Inc. (TER) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teradyne, Inc. vs GeneDx Holdings Corp — how do they compare? Teradyne, Inc. trades at $374.54 (market cap $52.25B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Teradyne, Inc. is far larger — about 29× GeneDx Holdings Corp's market cap, and Teradyne, Inc. pays a 0.16% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| TER | WGS | |
|---|---|---|
Market Cap | $52.25B | $1.80B |
Sector | Technology | Technology |
52-Week High | $483.84 | $167.51 |
52-Week Low | $90.15 | $34.51 |
Enterprise Value | $52.08B | $1.80B |
Dividend Yield | 0.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Teradyne (TER) trades at $374.15, up 16.07% in 24 hours, with strong quarterly earnings beats and robust AI-driven semiconductor testing demand. The stock shows bearish technical signals but maintains solid fundamentals with 22.55% net income margin and 28.75% ROE. Recent institutional activity includes Amova Asset Management reducing its position by 49.5% in Q1 2026 while maintaining bullish analyst consensus.
TER presents compelling growth potential from AI infrastructure expansion but faces valuation concerns with a 61.92 P/E ratio. The upcoming Q2 2026 earnings report on July 28, 2026, will be crucial for validating the AI-driven growth narrative. Risks include competitive pressures and market volatility, though analyst consensus targets $459.60 suggest 23% upside potential from current levels.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
